#envudeucitinib

Envudeucitinib for Psoriasis | Docwire News In two phase 3 studies, envudeucitinib improved skin clearance and signs and symptoms of psoriasis when compared with placebo or apremilast.

According to data presented at #AAD2026 by Dr Andrew Blauvert, #envudeucitinib improved signs and symptoms of #psoriasis compared with placebo or #apremilast.

www.docwirenews.com/post/envudeu...

Alumis Posts Phase 3 Psoriasis Results for Envudeucitinib Alumis said on Mar 28, 2026 its Phase 3 trial for envudeucitinib met the primary endpoint at Week 12; full PASI and safety tables will be released in coming weeks.

Alumis Posts Phase 3 Psoriasis Results for Envudeucitinib: Alumis said on Mar 28, 2026 its Phase 3 trial for envudeucitinib met the primary endpoint at Week 12; full PASI and safety tables will be released in… 👈 Read full analysis #Psoriasis #ClinicalTrials #Envudeucitinib #Phase3Trials #Dermatology